| 1496 |
National Cancer Institute |
Html |
en |
Chronic Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of chronic myeloproliferative neoplasms. |
| chronic idiopathic myelofibrosis | 0.460932 |
| -associated myelofibrosis | 0.377277 |
| primary myelofibrosis | 0.76249 |
| agnogenic myeloid metaplasia | 0.307689 |
| prognostic factors | 0.222887 |
| peripheral blood | 0.22296 |
| Mayo Clin Proc | 0.241864 |
| Lasho TL | 0.217158 |
| Br J Haematol | 0.259671 |
| blood cell transfusions | 0.218297 |
| Engl J Med | 0.445409 |
| red blood cell | 0.333388 |
| aforementioned prognostic systems | 0.209417 |
| JAK2-negative primary myelofibrosis | 0.455533 |
| Myelofibrosis Research | 0.385033 |
| peripheral blood myelophthisis | 0.21294 |
| Mesa RA | 0.470382 |
| myeloid metaplasia | 0.871911 |
| myeloproliferative neoplasms | 0.310964 |
| teardrop-shaped red blood | 0.217055 |
| myelofibrosis | 0.915542 |
| retrospective review | 0.217962 |
| Vera Study Group | 0.206315 |
| Abstract | 0.596486 |
|
| therapy | 0.209486 |
| patients | 0.479624 |
| Clin Oncol | 0.364567 |
| postoperative subcutaneous heparin | 0.256357 |
| Bone Marrow Transplant | 0.217694 |
| blood | 0.376461 |
| bone marrow | 0.283097 |
| thrombocythemia myelofibrosis | 0.453249 |
| blood cell survival | 0.22308 |
| peripheral blood granulocytes | 0.213686 |
| idiopathic myelofibrosis | 0.478488 |
| Asymptomatic low-risk patients | 0.236666 |
| Leuk Lymphoma | 0.295111 |
| International Prognostic Scoring | 0.257794 |
| clinical prognostic parameters | 0.20507 |
| high phlebotomy requirement | 0.203305 |
| post–essential thrombocythemia myelofibrosis | 0.447393 |
| allogeneic stem cell | 0.353702 |
| low-risk patients | 0.238481 |
| acute myelofibrosis | 0.423026 |
| blood cell transfusion | 0.227086 |
| et al. | 0.52463 |
| JAK inhibitors | 0.215327 |
|
CLICK HERE |
| 1703 |
National Cancer Institute |
Html |
en |
Tumor Grade |
A fact sheet that discusses tumor grade and its role in prognosis. Explains concepts like normal cell biology and cell differentiation. |
| Gleason score | 0.401724 |
| NCI fact sheet | 0.404685 |
| lower grade | 0.405507 |
| tissue organization | 0.400496 |
| better prognosis | 0.354968 |
| tumor tissue | 0.703634 |
| type-specific grading systems | 0.412132 |
| tumor type | 0.491464 |
| cancer cells | 0.405656 |
| biopsied tissue | 0.413701 |
| Gleason scores | 0.355221 |
| primary brain tumors | 0.42294 |
| tumor size | 0.501863 |
| abnormal-looking cells | 0.400459 |
| Nottingham grading | 0.360235 |
| higher-grade cancer | 0.364598 |
| tumor cells | 0.631844 |
| normal cells | 0.49423 |
| nearby lymph nodes | 0.408457 |
| tumor grade | 0.785451 |
| regional lymph node | 0.409603 |
| secondary pattern | 0.388809 |
| breast tumors | 0.384185 |
| Scarff-Bloom-Richardson grading | 0.361738 |
|
| normal tissue structures | 0.487646 |
| primary pattern | 0.353415 |
| microscopic examination | 0.353649 |
| breast cancer | 0.39308 |
| biopsy samples | 0.354483 |
| Staging page | 0.357155 |
| microscopic appearance | 0.359178 |
| different types | 0.358151 |
| tumors | 0.490957 |
| prostate cancer | 0.440387 |
| cancer staging | 0.368981 |
| slower rate | 0.360886 |
| American Joint Committee | 0.39399 |
| tumor | 0.981653 |
| tumor grades | 0.501473 |
| common tissue pattern | 0.44497 |
| cancer | 0.557882 |
| total score | 0.354108 |
| soft tissue sarcoma | 0.443518 |
| prostate cancers | 0.367392 |
| Gleason scoring | 0.35738 |
| tumor tissue look | 0.635152 |
| cancer stage | 0.457333 |
|
CLICK HERE |
| 1806 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de estómago (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de estómago. |
| after d2 gastrectomy | 0.313513 |
| gastrectomÃa d2 | 0.31496 |
| Cunningham D | 0.34388 |
| Macdonald JS | 0.318723 |
| Chemoradiotherapy after surgery | 0.344328 |
| randomised controlled | 0.319618 |
| combined modality therapy | 0.360634 |
| mejorÃa significativa | 0.31176 |
| Stenning SP | 0.310838 |
| intergroup trial calgb | 0.31542 |
| Postoperative adjuvant chemoradiation | 0.322032 |
| after ci 5-fu | 0.317294 |
| fase iii | 0.364462 |
| Estados Unidos | 0.347269 |
| with s-1 | 0.314235 |
| randomized trial comparing | 0.314288 |
| quimiorradioterapia posoperatoria | 0.360835 |
| ensayo rtog-9904 | 0.324678 |
| patients with | 0.484752 |
| adyuvante versus tasa | 0.360686 |
| supportive care | 0.325372 |
| Clinical Oncology | 0.311085 |
| Perioperative chemotherapy versus | 0.334581 |
| chemotherapy plus best | 0.312401 |
| Smalley SR | 0.318682 |
|
| with surgery | 0.339493 |
| Ajani JA | 0.354002 |
| or gastroesophageal junction | 0.340588 |
| ensayo swog-s0425 | 0.324881 |
| Allum WH | 0.311046 |
| quimiorradioterapia adyuvante versus | 0.364135 |
| estadio ib | 0.338006 |
| gastrectomÃa curativa d2 | 0.319296 |
| Van Cutsem E | 0.313883 |
| Benedetti J | 0.318647 |
| quimioterapia perioperatoria | 0.352185 |
| gastric carcinoma | 0.325701 |
| gastric cancer | 0.935626 |
| Clin Oncol | 0.612714 |
| or gastro-oesophageal junction | 0.317111 |
| trial comparing | 0.314461 |
| supportive care with | 0.324232 |
| Winter K | 0.319459 |
| Gastric Cancer Study | 0.317632 |
| chemotherapy versus surgery | 0.338116 |
| grupo s-1 | 0.317965 |
| Okawara GS | 0.319919 |
| care with best | 0.314996 |
| quimioterapia posoperatoria | 0.31518 |
|
CLICK HERE |
| 1875 |
National Cancer Institute |
Html |
es |
Tratamiento del linfoma relacionado con el sida (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del linfoma relacionado con el sida. |
| aids-related non-hodgkin lymphomas | 0.608138 |
| non-hodgkin's lymphomas | 0.666621 |
| prognostic factors | 0.350902 |
| HIV-associated Hodgkin | 0.399104 |
| Spina M | 0.351065 |
| linfoma hodgkin | 0.348723 |
| Epstein-Barr virus | 0.393918 |
| atypical burkitt lymphoma | 0.351153 |
| large b-cell lymphoma | 0.344814 |
| HIV-related lymphoma | 0.343107 |
| immunodeficiency virus | 0.402901 |
| highly active | 0.512378 |
| human immunodeficiency virus-associated | 0.403779 |
| Burkitt lymphoma | 0.387609 |
| immunodeficiency virus-associated non-Hodgkin | 0.342734 |
| AIDS patients with | 0.376046 |
| Dunleavy K | 0.344239 |
| Natl Cancer Inst | 0.464946 |
| active antiretroviral therapy | 0.726916 |
| central nervous system | 0.649203 |
| human immunodeficiency virus-related | 0.374511 |
| HIV-infected patients with | 0.343338 |
| immunodeficiency syndrome-related lymphoma | 0.354213 |
| lymphoma treated with | 0.43581 |
| patients with | 0.924942 |
|
| patients with primary | 0.375652 |
| chemotherapy with | 0.357715 |
| human immunodeficiency | 0.754154 |
| patients with aids-related | 0.424038 |
| oral t-cell lymphoma | 0.346331 |
| acquired immunodeficiency syndrome-related | 0.357324 |
| lymphoma is dramatically | 0.348699 |
| immunodeficiency virus-related lymphoma | 0.359105 |
| acquired immunodeficiency | 0.378848 |
| aids-related lymphoma | 0.736141 |
| treatment with | 0.389583 |
| primary central nervous | 0.521797 |
| Intern Med | 0.353617 |
| Clin Oncol | 0.792214 |
| sistema nervioso central | 0.421872 |
| systemic aids-related non-hodgkin | 0.367456 |
| non-hodgkin lymphoma | 0.744829 |
| Hodgkin lymphoma treated | 0.362251 |
| study with | 0.356196 |
| hiv-associated lymphomas | 0.544837 |
| primary effusion lymphoma | 0.456053 |
| nervous system lymphoma | 0.736571 |
| células b | 0.35592 |
| AIDS-related primary lymphoma | 0.361221 |
|
CLICK HERE |
| 1943 |
National Cancer Institute |
Html |
es |
Síndromes cardiopulmonares (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca de las afecciones comunes que producen síntomas en el tórax. Los síndromes cardiopulmonares que se exponen en este sumario son la disnea relacionada con el cáncer, el derrame pleural maligno, el derrame pericárdico y el síndrome de la vena cava superior. |
| pleural catheter | 0.17861 |
| Ripamonti C | 0.130559 |
| dificultad respiratoria | 0.26023 |
| malignant effusion | 0.115362 |
| lung cancer | 0.190962 |
| Sin embargo | 0.114284 |
| end-of-life patients with | 0.119385 |
| indwelling pleural catheter | 0.162022 |
| Dudgeon DJ | 0.13043 |
| fármacos pleurales esclerosantes | 0.112004 |
| disfunción muscular respiratoria | 0.121219 |
| Hematol Oncol Clin | 0.143013 |
| hypoxemic patients with | 0.118489 |
| patients receiving chemotherapy | 0.111162 |
| Cancer Organisation Thoracic | 0.117844 |
| antitusivos opioides | 0.112496 |
| recurrent symptomatic malignant | 0.110714 |
| patients with | 0.625852 |
| insuficiencia cardiaca | 0.134239 |
| Pain Symptom Manage | 0.478956 |
| randomized controlled | 0.112081 |
| pleural fluid | 0.136904 |
| Cancer Dyspnea Scale | 0.146703 |
| Moroni M | 0.110841 |
| Care Cancer | 0.128094 |
|
| pleural catheter vs | 0.135869 |
| Physiol Neurobiol | 0.116436 |
| as symptomatic treatment | 0.110943 |
| derrame maligno fracasa | 0.114534 |
| obstructiva crónica | 0.135859 |
| vÃas respiratorias | 0.205286 |
| tunnelled pleural catheter | 0.139919 |
| tos crónica causa | 0.111919 |
| prospective randomized | 0.110614 |
| pleural effusions with | 0.149859 |
| Intern Med | 0.132242 |
| Clin Oncol | 0.11762 |
| Med Pediatr Oncol | 0.111608 |
| Clin North Am | 0.136363 |
| Bruera E | 0.203018 |
| systematic review | 0.116364 |
| Oncol Clin North | 0.140711 |
| American Thoracic Society | 0.114142 |
| as palliative treatment | 0.110799 |
| malignant pleural effusions | 0.900896 |
| Crit Care Med | 0.171232 |
| symptomatic malignant | 0.122652 |
| alone versus | 0.11566 |
| compared with | 0.110951 |
|
CLICK HERE |
| 1944 |
National Cancer Institute |
Html |
es |
Síndromes cardiopulmonares (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de las afecciones comunes que producen síntomas en el pecho. Los síndromes cardiopulmonares que se exponen en este sumario son la disnea relacionada con el cáncer, la efusión pleural maligna, la efusión pericárdica y el síndrome de la vena cava superior. |
| neoplásico pericárdico | 0.570337 |
| aurÃculas derecha | 0.413336 |
| siguientes procedimientos | 0.476145 |
| suficiente sangre | 0.429294 |
| disnea ayuda | 0.428346 |
| siguientes elementos | 0.427349 |
| PDQ SÃndromes cardiopulmonares | 0.420075 |
| aurÃcula derecha | 0.413308 |
| pequeña cantidad | 0.419135 |
| lÃquido allà | 0.447596 |
| cuerpo.ampliar radiografÃa | 0.576347 |
| siguientes tipos | 0.416182 |
| sÃndromes cardiopulmonares | 0.693009 |
| rayos x | 0.496155 |
| suficiente oxÃgeno | 0.422453 |
| largo plazo | 0.415907 |
| menudo causa infecciones | 0.442964 |
| esclerosis pericárdica procedimiento | 0.439765 |
| obstructiva crónica | 0.420705 |
| pleural extracción | 0.480399 |
| vÃas respiratorias | 0.858731 |
|
| máxima presión | 0.42053 |
| National Cancer Institute | 0.411568 |
| pleural maligno | 0.991379 |
| vÃa respiratoria | 0.496611 |
| suficiente aire | 0.455692 |
| Ascitis Extracción | 0.422054 |
| siguientes tratamientos | 0.411554 |
| pequeñas vÃas respiratorias | 0.434391 |
| PericardiotomÃa Procedimiento | 0.427972 |
| Instituto Nacional | 0.420501 |
| pericárdico extracción | 0.450036 |
| siguientes problemas | 0.422606 |
| siguientes factores | 0.415522 |
| Physician Data Query | 0.44175 |
| haz angosto | 0.421283 |
| linfangitis carcinomatosa terapia | 0.435827 |
| PericardiectomÃa CirugÃa | 0.416216 |
| mala nutrición | 0.417318 |
| insuficiencia cardÃaca | 0.522457 |
| superior quimioterapia | 0.453603 |
| procedimiento ayuda | 0.419009 |
|
CLICK HERE |
| 2082 |
National Cancer Institute |
Html |
en |
Cancer Clusters |
A fact sheet that describes what constitutes a cancer cluster and the process for reporting and investigating suspected clusters. |
| major risk factor | 0.385962 |
| specific environmental hazards | 0.38074 |
| rare cancer | 0.409989 |
| website uses data | 0.380594 |
| cancer trends | 0.398646 |
| individual cancer clusters | 0.469731 |
| number | 0.405815 |
| investigators | 0.393508 |
| Health Hazard Evaluation | 0.380995 |
| Disease Control | 0.519415 |
| Health Consultations page | 0.381331 |
| cancer cluster | 0.895701 |
| cancer clusters | 0.841764 |
| National Center | 0.381056 |
| ATSDR regional offices | 0.380684 |
| different geographic area | 0.38274 |
| cluster investigations | 0.411002 |
| true cancer clusters | 0.482566 |
| public health assessments | 0.472612 |
| statistically significant difference | 0.384068 |
| vinyl chloride | 0.380035 |
| specific cancer type | 0.434002 |
| primary cancer | 0.413707 |
| U.S. Census Bureau | 0.37492 |
| specific hazardous substances | 0.37613 |
|
| different cancer types | 0.429181 |
| state health department | 0.450442 |
| total number | 0.385248 |
| cancer cases | 0.749447 |
| health departments | 0.457783 |
| NCI analyze variations | 0.380726 |
| local health departments | 0.450682 |
| geographic area | 0.518161 |
| specific geographic area | 0.389344 |
| health surveillance programs | 0.382617 |
| people | 0.378106 |
| epidemiologic study | 0.378396 |
| agency gathers information | 0.381997 |
| statistically significant excess | 0.455543 |
| secondary cancer | 0.393665 |
| cancer | 0.954313 |
| state cancer registries | 0.443891 |
| cancer cluster—that | 0.391887 |
| Disease Registry | 0.381886 |
| specific time period | 0.392616 |
| Toxic Substances | 0.380998 |
| cancer death rates | 0.436653 |
| cancer incidence | 0.401099 |
| Cancer Mortality Maps | 0.435229 |
|
CLICK HERE |
| 3564 |
National Cancer Institute |
Html |
en |
The NCI Intramural Research Program |
The intramural research program supports projects conducted by scientists located at NCI. |
| intramural cancer research | 0.718907 |
| intramural research program | 0.874728 |
| public health issues | 0.586317 |
| IRP researchers | 0.99482 |
| clinical disciplines | 0.535611 |
| basic research discovery | 0.633697 |
| cancer initiation | 0.556039 |
| NCI offices | 0.598153 |
| private sector partners | 0.575197 |
| long-term cohort studies | 0.573663 |
| NCI intramural research | 0.823709 |
| extramural institutions | 0.555913 |
| future research | 0.545095 |
| clinical trials | 0.610273 |
| sophisticated statistical approaches | 0.591904 |
| outstanding scientific credentials | 0.582191 |
| rare cancers | 0.616347 |
| outstanding research | 0.546529 |
| clinical IRP researchers | 0.677303 |
| extramural investigators | 0.808101 |
| basic scientific research | 0.670523 |
| cervical cancer | 0.590079 |
| traditional funding mechanisms | 0.574359 |
| Early-stage clinical trials | 0.595705 |
|
| intramural researchers | 0.664665 |
| Cancer Epidemiology | 0.564756 |
| population-based research | 0.591379 |
| various reasons—to fund | 0.579705 |
| National Cancer Program | 0.628399 |
| cancer prevention | 0.546859 |
| noninfectious virus-like particles | 0.5887 |
| relatively little funding | 0.573973 |
| cancer research | 0.783668 |
| academic institutions | 0.606037 |
| high-reward research | 0.541951 |
| NCI IRP | 0.623146 |
| CCR’s John | 0.543838 |
| NIH Clinical Center | 0.948229 |
| public health needs | 0.603453 |
| Intramural research projects | 0.689496 |
| research program complement | 0.627977 |
| basic cancer research | 0.675487 |
| research resources | 0.556851 |
| CCR researcher Ira | 0.613887 |
| NCI components | 0.59726 |
| CCR colleagues | 0.538611 |
| cancer risk | 0.53862 |
| federal government investigators | 0.655439 |
|
CLICK HERE |
| 15648 |
National Cancer Institute |
Html |
en |
NCI Grant Policies |
Research grants are subject to a variety of policy requirements. Find highlights of policy announcements or changes specific to NCI. |
| Large R01s | 0.450134 |
| intramural investigators | 0.495879 |
| P01 renewal applications | 0.616984 |
| comprehensive access | 0.459855 |
| research grants | 0.682427 |
| specific policy | 0.488359 |
| evidence-based approaches | 0.457301 |
| human health | 0.466536 |
| Access Policy | 0.490853 |
| cancer therapy | 0.46631 |
| budget request | 0.487575 |
| prior approval | 0.46826 |
| clinical trials | 0.978226 |
| alternative calculation | 0.447591 |
| NIH Grants Policy | 0.785706 |
| additional information | 0.464918 |
| unsolicited R01 applications | 0.694664 |
| exceptions | 0.333503 |
| NIH GDS policy | 0.707591 |
| cooperative agreements | 0.455552 |
| research results | 0.500906 |
| direct cost requests | 0.569063 |
| PARs | 0.332254 |
| grants administration policies | 0.684335 |
| cancer research continuum | 0.601742 |
|
| NCI-Supported Interventional Clinical | 0.650424 |
| non-NIH funded investigators | 0.630213 |
| NIH research | 0.564712 |
| contracts | 0.352239 |
| large R01 payline | 0.833282 |
| NCI Clinical Trials | 0.784254 |
| genomic research data | 0.651702 |
| final results | 0.607682 |
| general R01 payline | 0.832292 |
| NCI Program Director | 0.732659 |
| Scientific Review | 0.449688 |
| budget format | 0.487382 |
| grantees | 0.329888 |
| NIH Guide | 0.534988 |
| interventional clinical trials | 0.88994 |
| deviation | 0.332851 |
| directly impact patient | 0.587395 |
| policy announcements | 0.520246 |
| Type | 0.343808 |
| policy requirements | 0.522004 |
| separate NCI payline | 0.844339 |
| interventional cancer research | 0.663219 |
| prior project period | 0.601145 |
| direct cost budget | 0.622892 |
|
CLICK HERE |
| 17279 |
National Cancer Institute |
Html |
es |
Planes para atender un cáncer avanzado |
Una planificación cuidadosa reducirá el peso que enfrentará su familia más adelante. La planificación puede incluir aspectos económicos y legales, pero como verá, también puede ser una forma de celebrar su vida y de darle significado. |
| tensiones. Algunas personas | 0.876955 |
|
|
CLICK HERE |